PRESS RELEASE
Imexpharm successfully holds its 2026 Annual General Meeting of Shareholder
• Imexpharm continues to target double-digit growth, with net revenue, profit before tax, and EBITDA projected to increase by 10.1%, 12.6%, and 12.3%, respectively (compared to 2025).
• Backed by over a decade of EU-GMP expertise and together with technology collaborations with specialized pharmaceutical partners, Imexpharm is well-positioned to scale new heights in its next phase of growth.
• All resolutions were approved by shareholders.
HCMC, April 22, 2026 - Imexpharm Corporation (“Imexpharm” or the “Company,” IMP.VN), one of the leading pharmaceutical companies in Vietnam, successfully held its 2026 Annual General Meeting of Shareholders (AGM) at the New World Saigon Hotel, 76 Le Lai Street, Ben Thanh Ward, Ho Chi Minh City.
At the AGM, shareholders approved all resolutions, encompassing key matters including the 2025 profit distribution and dividend payment, the 2026 dividend and business plans, the Board of Directors’ remuneration and operating budget, the appointment of the external auditor for 2026, and amendments to the Company’s business lines and Charter.
2025: Agile and resilient adaptation – reinforcing leadership in the antibiotics and cough medicine segments
In 2025, Imexpharm recorded gross revenue of VND 2,914 billion, up 16.0%, and net revenue of VND 2,441 billion, up 10.7% year-on-year, driven by a well-executed product portfolio shift and distribution channel strategy. Gross profit increased by 17.1%, bringing the gross margin to 41.0%, reflecting improved production efficiency and cost management. Profit before tax reached VND 446 billion, up 10.4% year-on-year, achieving 90% of the AGM target despite policy-related market fluctuations.
The Board of Directors and Management assessed the Company’s 2025 performance as solid, outperforming market benchmarks. Shareholders also approved a 6% cash dividend, exceeding the plan by 1%, underscoring Imexpharm’s commitment to delivering shareholder value and sustainable growth.
In 2025, Imexpharm implemented 157 projects and launched 25 new products (SKUs), exceeding its plan. Notably, the Company introduced Vietnam’s first “first generic” antibiotic (Ceftazidime/Avibactam 2.5g) manufactured on an EU-GMP-compliant production line, further strengthening its long-term competitive advantage.
At the AGM, Ms. Tran Thi Dao, Board Member and General Director of Imexpharm, stated: “2025 marks the 10th anniversary of a proud journey, a decade of manufacturing and distributing EU-GMP-compliant pharmaceuticals in Vietnam. Over the past ten years, we have established and maintained our position as Vietnam’s leading EU-GMP pharmaceutical manufacturer, driven by a long-term strategic vision and disciplined execution. This ‘10-year EU-GMP journey’ also represents a significant milestone, underscoring the exceptional and hard-to-replicate capabilities of the Imexpharm team in research, manufacturing, and quality management, ensuring that every product delivered to patients provides the highest level of confidence in safety and treatment effectiveness.”
2026: Leveraging strong EU-GMP foundation, R&D capabilities, and technology to scale new heights
The AGM also approved the 2026 business plan, targeting gross revenue of VND 3,200 billion, with all key financial indicators expected to maintain double-digit growth:
· Profit before tax: up 12,5% yoy
· EBITDA: up 12,3% yoy
The company’s management board noted that 2026 is expected to remain a year of heightened uncertainty. While Vietnam’s economy is projected to sustain one of the strongest growth rates in ASEAN, geopolitical risks, exchange rate volatility, interest rates, and inflationary pressures are likely to continue posing challenges.
Against this backdrop, Imexpharm has structured its 2026 and mid-term strategy around three core pillars: Technology - Products, Market, and Governance.
On the technology and product front, Imexpharm is intensifying strategic collaborations with leading pharmaceutical partners, to acquire advanced technologies and co-develop high-value, specialized therapies. These partnerships are executed under stringent risk management frameworks, leveraging complementary strengths alongside the Company’s core capabilities in EU-GMP manufacturing, R&D, and strong local market insights.
On the market front, Imexpharm continues to strengthen its domestic position while expanding its presence in Northern Vietnam through the establishment of a Hai Phong branch. The Company is also accelerating global expansion by maintaining and extending EU-MAs and ASEAN licenses, along with selective distribution agreements.
Regarding governance, Imexpharm is enhancing its standards toward international benchmarks, focusing on strategic, financial, and compliance risk management. The Company is implementing IFRS, accelerating digital transformation in reporting systems, and strengthening data-driven decision-making to build a transparent and efficient governance platform.
In parallel, the Cat Khanh Pharmaceutical Complex Project (IMP5), with a total investment of nearly VND 1,500 billion, is progressing in line with financial capacity and market demand. The project focuses on high-tech and specialized treatment products and is expected to become a key growth driver, with phased commercial operations from late 2028 to Q1 2030.
The AGM also approved a cash dividend plan for 2026, with a projected payout ratio of 5% to 8% of charter capital, subject to actual business performance.
The Company’s leadership emphasized: “Entering 2026, Imexpharm continues to transform and grow in rhythm with evolving market dynamics. We are well-positioned to strengthen our leadership in existing markets while accelerating into new growth areas”.
Q&A with Shareholders: Key topics of interest
The discussion session at the 2026 Annual General Meeting of Shareholders (AGM) clearly reflected shareholders’ strong interest in key strategic issues, ranging from product portfolio and long-term competitiveness to the progress of key projects, ownership structure, and the participation of a new strategic investor.
Amid intensifying competition in the EU-GMP segment of the ETC channel, shareholders expressed particular concern over the growth drivers that will enable Imexpharm to sustain revenue growth in 2026 and the years ahead. Addressing this, Mr. Vu Dinh Xuan, Sales Director of Imexpharm, noted that the Company has entered its 11th year of EU-GMP compliance, demonstrating extensive experience and strong execution capabilities under EU-GMP standards, an important differentiator versus other EU-GMP manufacturers. While increased competition is inevitable, Imexpharm continues to maintain key advantages, including: optimized production costs as its plants have been depreciated over the past 10 years; a focus on developing high-tech products; diversification of the OTC portfolio through expanded partnerships with modern pharmacy chains; and increased market penetration in Northern Vietnam.
In response to shareholder inquiries regarding the development progress of the chronic disease treatment portfolio, Mr. Le Van Nha Phuong, Deputy General Director cum Chief Production Officer, stated that, in addition to nearly 160 R&D projects ready for production on the existing four manufacturing clusters, the Company has initiated the review and selection of a pipeline of approximately 150 products for the Cat Khanh Pharmaceutical Complex Project. This includes next-generation antibiotics, with nearly 50% comprising chronic disease treatments. The portfolio has been assessed based on domestic market demand and the R&D team’s capabilities. The Company is also engaging with partners to explore technology transfer opportunities, aiming to ensure success and accelerate the development of new key R&D projects. However, the final portfolio will be subject to approval by the Board of Directors in subsequent phases of the Cat Khanh project, expected by late this year or early 2027.
Another topic of strong shareholder interest is the potential participation of new strategic investors. Pharmacist Tran Thi Dao, Board Member and General Director of Imexpharm, stated that such participation is expected to enhance Imexpharm’s R&D capabilities, facilitate access to advanced technologies, and strengthen its long-term competitiveness.
Regarding the construction progress of the Cat Khanh Pharmaceutical Complex Project, Mr. Ngo Minh Tuan, Deputy General Director cum Chief Operating Officer, shared that the project has a total investment of VND 1,495 billion and a designed capacity of 1.4 billion units per year, covering both injectable and oral drugs. The project will be implemented in three phases. Phase 1 focuses on infrastructure, warehousing, and one manufacturing plant, expected to achieve WHO-GMP certification by Q4 2028. Phase 2 will be implemented from 2031 to 2035 in line with production expansion plans, while Phase 3 (2036–2039) will support the relocation of existing plants under the IMP1 cluster.
Commenting on biologics, Mr. Vu Dinh Xuan noted that the emergence of biologic drugs has brought significant advantages that conventional small-molecule drugs have not been able to achieve. As a result, major global pharmaceutical companies are increasingly shifting their focus toward biologics research, driven by their superior efficacy, economic value, profitability, and greater resistance to generic replication.
“Currently, biologics account for over 40% of total global drug value, and this figure is expected to exceed 50% by 2030. In Vietnam, the proportion is similar, with biologics representing around 40% of total drug value (despite accounting for only about 1–3% of volume), mainly in vaccines, oncology, immunology, diabetes, and hormonal therapies. Therefore, it can be affirmed that biologics (and biosimilars) present substantial growth potential in both the Vietnamese market and globally, both in the present and in the future.”
About Imexpharm
Imexpharm is a leading company in the production and distribution of high-quality antibiotics in Vietnam. With nearly five decades of development, the Company has consistently been at the forefront of the Vietnamese pharmaceutical industry, driven by international partnerships and adherence to the highest standards of safety and quality. Imexpharm is well-positioned for growth in both domestic and international markets, supported by a strong strategic and financial foundation, and continues to expand its product portfolio into new therapeutic areas and healthcare segments.
For media inquiries, please contact:
Ms. Le Thanh Hang, IR Director hanglt@imexpharm.com +84 287 304 8939